Stony Hill Corp. (OTCMKTS:STNY) Files An 8-K Other Events

Stony Hill Corp. (OTCMKTS:STNY) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events

Establishment of AdvisoryBoard and Adoption of

On April 28, 2017, the Stony Hill Corp., a Nevada corporation
(the Company), announced that the Board of the Directors of the
Company has established an advisory board (the Advisory Board)
and approved and adopted a charter (the Advisory Board Charter)
to govern the Advisory Board. to the Advisory Board Charter, the
Advisory Board shall be comprised of one or more directors, and
up to six independent, non-Board, non-employee members, all of
whom shall be appointed and subject to removal by the Board of
Directors at any time. In addition to the enumerated
responsibilities of the Advisory Board in the Advisory Board
Charter, the primary function of the Advisory Board is to assist
the Board of Directors in its general oversight of the Companys
development of new business ventures and strategic planning. A
copy of the Companys Advisory Board Charter is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

In connection with the establishment of the Advisory Board, the
Board of Directors appointed Dr. James Mul, an independent,
non-Board and non-Company employee to the Advisory Board.
Currently, the Advisory Board does not have a Company director
member, and Dr. Mul is its sole member.

In connection with Dr. Muls appointment to the Advisory Board,
the Company entermeted into a Consulting Agreement (the
Consulting Agreement), dated effective May 1, 2017, whereby the
Company shall pay Dr. Mul an annual consulting fee of $50,000
worth of shares of common stock of the Company, based on the
stock price of the Company on the last day of each calendar year,
and reimburse Dr. Mul for reasonable out-of-pocket expenses,
including, without limitation, travel expenses incurred by him in
connection with the Companys requests of the performance of his
duties to the Company. In addition, the Dr. Mul may be eligible
for an annual discretionary bonus based on performance and
entirely at the discretion of Board. The Consulting Agreement has
a term of three years.

Dr. Mul is Associate Center Director, the U.S. Senator Connie
Mack (ret.) Family Endowed Chair for Melanoma Research and
Treatment, and Director of Cell-based Therapies at the Moffitt
Cancer Center, Tampa, Florida. He is recognized for his research
and clinical trial contributions to cancer immunotherapy,
particularly in melanoma. His translational work in this area has
helped to develop new treatments for advanced cancer patients. He
has published nearly 200 articles. Dr. Mul serves on Advisory
Boards of numerous biotechnology and pharma companies as well as
investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac,
Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select
BioVenture Partners, Noble Life Science Partners, KB Capital
Management, among others). Dr. Mul remains a long-standing
special government employee to the FDA (CDER and CBER) and the
NCI. He was Chair of the Cellular, Tissue, and Gene Therapy
Advisory Committee of CBER , FDA. He currently serves on the
advisory boards of several NCI-designated Cancer Centers and was
a member of the NCI Directors Board of Scientific Counselors
(BSC-A). Dr. Mul also serves on the Editorial Boards of several
peer-reviewed journals, including Scientific Reports
(, Journal of Immunotherapy, and Cancer Immunology
Research (AACR). Dr. Mul received his professional degrees from
the Fred Hutchinson Cancer Research Center and the University of
Washington, Seattle, Washington. He then received his formal
post-graduate training at the Surgery Branch , Division of Cancer
Treatment, National Cancer Institute, NIH, Bethesda, Maryland,
where he became a Senior Investigator with tenure. Dr. Mul moved
to Palo Al to, CA, where he helped to launch and scientifically
direct two biotechnology companies and was also an adjunct
professor at Stanford University. He then moved to Ann Arbor,
Michigan to become the Director of the Tumor Immunology and
Immunotherapy Program at the University of Michigan Comprehensive
Cancer Center, the Maude T. Lane Endo wed Professor of Surgery
with tenure, Department of Surgery, and Professor in the
Department of Internal Medicine.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Consulting Agreement, dated May 1, 2017, by and between the
Company and Dr. James Mul


AdvisoryBoard Charter, adopted by the Board of Directors of
Stony Hill Corp. on April 18, 2017


About Stony Hill Corp. (OTCMKTS:STNY)

Stony Hill Corp., formerly First Fixtures, Inc., is organized to sell plumbing fixtures over the Internet. The Company is a vertically integrated company focused on multiple areas of the cannabis industry. The Company is engaged in exploring involvement in the consumer, health and wellness, recreational, medical, media and nutraceutical industry. The Company sells products, including clothing, apparel, and other various branded products through its partners. Stony Hill Ventures is organized for various investments under the Stony Hill brand, as well as to conduct any other related business and activities. The Company intends to establish a medical cannabis platform and brand; create a platform to partner and invest in various segments in the medical marijuana industry, and establishes various strategic alliances.

Stony Hill Corp. (OTCMKTS:STNY) Recent Trading Information

Stony Hill Corp. (OTCMKTS:STNY) closed its last trading session up +0.10 at 2.30 with 2,500 shares trading hands.

An ad to help with our costs